Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Outcomes of transscleral diode laser cyclophotocoagulation in refractory glaucoma patients with good visual acuity

Poster Details

First Author: G.Arikan TURKEY

Co Author(s):    T. Ozturk   B. Unlu   U. Gunenc              

Abstract Details

Purpose:

To evaluate the efficacy and safety of transscleral cyclophotocoagulation (TSCP) in refractory glaucoma patients with a best-corrected visual acuity (BCVA) of 0.1 or better.

Setting:

Dokuz Eylul University School of Medicine, Izmir, Turkey.

Methods:

Charts of patients underwent TSCP between January 2009 and June 2013 were reviewed retrospectively. Eyes with a baseline BCVA of 0.1 or better (≤ 1.0 logMAR) were included in the study. Overall success was defined as a final intraocular pressure (IOP) between 7 and 21 mmHg. Visual acuity scores, IOP levels and total number of antiglaucomatous medication were reviewed. Wilcoxon signed rank analysis, Mann-Whitney U and student t tests were used for statistics.

Results:

Ten eyes of 10 patients with a mean age of 48.1±22.6 years were included. Mean follow-up was 10.2±5.5 months. Diagnosis was primary open angle glaucoma in 8 eyes, aphakic glaucoma in 1 eye and neovascular glaucoma in 1 eye. In 3 eyes, TSCP was applied twice. Pretreatment BCVA and IOP were 0.46±0.35 logMAR and 27.2±6.4 mmHg, whereas they were 0.43±0.34 logMAR and 17.0±4.4 mmHg at the last visit (p=0.269 and p=0.001). Pretreatmently all cases were put on 4 antiglaucomatous medication that decreased to 2.85±0.38 after TSCP procedure (p=0.001). At the last visit, overall success was achieved in 7 eyes (70%).

Conclusions:

Transscleral diode laser cyclophotocoagulation is an effective IOP-lowering procedure; which can also be safely used in eyes with good visual acuity.

Financial Disclosure:

NONE

Back to Poster listing